Lornoxicam

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Non-steroidal anti-inflammatory drug from the Piroxicame group.

IndicationThis section has been translated automatically.

Pain therapy for arthritis, including rheumatoid arthritis, ankylosing spondylitis, pain in arthrosis or other underlying diseases.

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated (insufficient data on use in pregnancy; substance passes into breast milk in animal experiments).

Dosage and method of useThis section has been translated automatically.

  • Tbl.: 3-4 times/day 4 mg or 2 times/day 8 mg p.o. (to be taken before a meal with sufficient liquid). Max. Daily dose 16 mg, in patients with liver or kidney dysfunction 12 mg.
  • Suppositories: 2 times/day 1 supp. (12 mg), maximum daily dose: 24 mg.

Undesirable effectsThis section has been translated automatically.

  • Common (10-20% of patients with short-term treatment and 20-35% with long-term treatment): Gastrointestinal symptoms such as heartburn, nausea, vomiting, abdominal pain.
  • Rarely (1-2% of patients): cutaneous side effects such as maculopapular exanthema, urticaria, ecchymosis) etc. Rarely (about 5% of patients): tiredness, paresthesia, dizziness.

ContraindicationThis section has been translated automatically.

Application for Pat < 18 yrs (insufficient data). Hypersensitivity to the substance or cross-reactions to other non-steroidal anti-inflammatory drugs (including acetylsalicylic acid). Active stomach or intestinal ulcers, gastrointestinal bleeding. Severe liver or kidney failure.

PreparationsThis section has been translated automatically.

Telos

Note(s)This section has been translated automatically.

Remember! The ability to react in road traffic and when operating machines may be impaired!

Authors

Last updated on: 29.10.2020